The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global parkinson's disease treatment market is expected to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Parkinson’s disease refers to a progressive neurological disorder caused by the degeneration of motor neurons in the brain. It is characterized by rigidity, tremors, difficulty in walking, motor impairment, depression and dementia. Some of the common treatment options for this disorder include medications, supportive therapies and surgical procedures, such as deep brain stimulation. Medications include carbidopa-levodopa medicines, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors and anticholinergics. These treatment methods are highly effective in managing the symptoms of Parkinson’s disease and providing comfort to the patient in case of a seizure.
Global Parkinson's Disease Treatment Market Trends and Drivers:
The increasing prevalence of Parkinson’s disease, and the rising geriatric population across the globe, which is more susceptible to neurodegenerative ailments, represent as the key factors driving the growth of the market. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is also stimulating the market growth. In line with this, COMT inhibitors are gaining immense traction among healthcare providers and patients. They are administered along with co-therapeutic agents and carbidopa-levodopa therapy for maximum efficiency. Additionally, various innovations in the disease treatment methods, such as the development of neurostimulation tools, gene therapy and neural transplantation procedures, are acting as other growth-inducing factors. These procedures aid in prolonged action of unremitting dopaminergic stimulation medicines and facilitate slowing down the disease progression, which, in turn, is creating a positive outlook for the market. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global parkinson's disease treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class, route of administration and distribution channel.
Breakup by Drug Class:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, H. Lundbeck A/S , Merck & Co. Inc., Mylan N.V., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries and Wockhardt Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Class, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, H. Lundbeck A/S , Merck & Co. Inc., Mylan N.V., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries and Wockhardt Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at